Home

Merck & Co (MRK)

85.99
+0.00 (0.00%)
NYSE · Last Trade: Oct 13th, 8:07 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?fool.com
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via The Motley Fool · October 13, 2025
Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound
Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have staged a notable rebound. This split reaction, observed around October 12, 2025, highlights the immediate and often contrasting interpretations of heightened geopolitical risks and
Via MarketMinute · October 12, 2025
Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine a harsh light on persistent inflation. This report, due for release amidst an ongoing government shutdown, is
Via MarketMinute · October 10, 2025
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investmentsbenzinga.com
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.
Via Benzinga · October 10, 2025
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Via MarketMinute · October 9, 2025
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This proactive announcement, made well in advance of the payment date, underscores the company's consistent commitment to shareholder
Via MarketMinute · October 9, 2025
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This declaration, made on the current date of October 9, 2025, underscores the company's consistent commitment to shareholder
Via MarketMinute · October 9, 2025
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Via MarketMinute · October 9, 2025
Behind the Scenes of Merck & Co's Latest Options Trendsbenzinga.com
Via Benzinga · October 9, 2025
5 Healthcare Plays Powering the Sector’s Big Comebackmarketbeat.com
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via MarketBeat · October 9, 2025
Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccinebenzinga.com
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Via Benzinga · October 7, 2025
How Arcus Biosciences Aims To Take On Merck In Cancer Treatmentinvestors.com
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via Investor's Business Daily · October 7, 2025
1 Monster Stock in the Making to Buy and Holdfool.com
This biotech company was relatively unknown a few years ago.
Via The Motley Fool · October 5, 2025
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Marketsbenzinga.com
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via Benzinga · October 3, 2025
Merck & Co's Options: A Look at What the Big Money is Thinkingbenzinga.com
Via Benzinga · October 3, 2025
U.S. Jobs Report Stalled Amidst Federal Shutdown: A Critical Information Vacuum for Markets and Policymakers
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been delayed indefinitely. This immediate consequence of the government's funding lapse creates a significant blind spot for
Via MarketMinute · October 2, 2025
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheapbenzinga.com
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?fool.com
Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.
Via The Motley Fool · October 2, 2025
Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
Via MarketMinute · October 2, 2025
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
Via TokenRing AI · October 2, 2025
Wall Street Holds Firm Despite Shutdown and Weak Jobs Datachartmill.com
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood.
Via Chartmill · October 2, 2025
Why Merck (MRK) Stock Is Up Today
Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers. 
Via StockStory · October 1, 2025
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Yearsbenzinga.com
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via Benzinga · October 1, 2025
Wednesday's session: top gainers and losers in the S&P500 indexchartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · October 1, 2025
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.
Via Chartmill · October 1, 2025